Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198223 | 1.00 | MAPK1 (0.55) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL29631618 | 0.91 | MAPK1 (0.44) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9196919 | 0.90 | MAPK1 (0.58) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9197895 | 0.89 | MAPK1 (0.57) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9203461 | 0.88 | MAPK1 (0.55) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9199898 | 0.88 | MAPK1 (0.55) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9196732 | 0.87 | KMT2A (0.43) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9206336 | 0.86 | MAPK1 (0.64) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9196878 | 0.85 | MAPK1 (0.52) | MAPK1HSD17B10KMT2AMEN1NPC1 | |
| SCHEMBL9199871 | 0.85 | MAPK1 (0.52) | MAPK1HSD17B10KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659784-B | Water-based metallic paint for automotive original factory interior and exterior decoration as well as preparation method and application thereof | 雅图高新材料股份有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-117659784-A | Water-based metallic paint for automotive original factory interior and exterior decoration as well as preparation method and application thereof | 雅图高新材料股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12569464-B2 | Protein-protein interaction inducing technology | ARVINAS OPERATIONS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3169793-B1 | ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES | TANGEN BIOSCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114656452-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220162163-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-05-26 | — | — | US | disclosed |
| CN-112852273-B | Water-based matte scratch-resistant paint and application thereof | 惠州飞凯新材料有限公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220112211-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UNIV YALE (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | disclosed |
| CN-111440496-B | Water-based UV silver powder coating and preparation method and application thereof | 湖南松井新材料股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | MAPK1 4256/4885HSD17B10 540/4885KMT2A 2907/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | MAPK1 3925/4885HSD17B10 1690/4885KMT2A 3663/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | MAPK1 4310/4885HSD17B10 1858/4885KMT2A 1680/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | MAPK1 2686/4885HSD17B10 4399/4885KMT2A 2575/4885 |
| US-20220112211-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | MAPK1 3128/4885HSD17B10 3884/4885KMT2A 1660/4885 |
| US-12569464-B2 | Protein-protein interaction inducing technology | STUB1, MDM2, XIAP | MAPK1 2101/4885HSD17B10 3196/4885KMT2A 2356/4885 |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | MAPK1 3128/4885HSD17B10 3884/4885KMT2A 1660/4885 |
| US-20220162163-A1 | ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | XIAP, BIRC3, BIRC2 | MAPK1 3097/4885HSD17B10 2495/4885KMT2A 3179/4885 |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | MAPK1 3133/4885HSD17B10 3330/4885KMT2A 2256/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | MAPK1 2766/4885HSD17B10 3249/4885KMT2A 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.